分化型甲状腺癌术后碘-131清除残余甲状腺组织安全性分析

Abstract
Figure/Table
References (38)
Related Citation (15)

Download: PDF (449 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

In recent years, the incidence of thyroid cancer has been increasing in China. Differentiated thyroid cancer(DTC) is a kind of thyroid cancer, among which postoperative DTC combined with 131 iodine (131I) treatment has become a routine treatment for patients with middle and high risk of recurrence. Normal thyroid cells have the ability of iodine uptake, can selectively ingests 131I from the blood into normal thyroid follicular cells, using the physical decay of 131I to produce β-ray radiobiological effects, remove normal residual thyroid tissue, to reduce the purpose of tumor recurrence and metastasis. Although the clinical value of 131I in removing residual thyroid tissue is widely recognized,the ionizing radiation from the physical decay of 131I may cause ionizing damage to patients and the public, and clinicians should be fully aware of the risks. At present, there are few studies on the safety of different doses of 131I for patients and the public, and the long-term effects of 131I on patients are still controversial. In this paper, the safety of 131I removal of residual thyroid tissue after DTC on hematopoietic system, reproductive system, secondary tumor and public radiation are briefly described.

Key words： Differentiated thyroid cancer Iodine -131 treatment Security Ionizing radiation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Junhua
	ZENG Tianyu
	QIN Yongzhang
	LYU Weiming

Cite this article:

DENG Junhua,ZENG Tianyu,QIN Yongzhang, et al. Safety analysis of iodine-131 removal of residual thyroid tissue after surgery for differentiated thyroid cancer[J]. 中国当代医药, 2022, 29(26): 35-39.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I26/35

[1]	周乐，张广，张大奇，等.细针穿刺活检及洗脱液检测在甲状腺癌颈淋巴结清扫决策中的应用研究[J].中国实用外科杂志，2017，37（9）：1002-1006.
[2]	周伟，陈易来，詹维伟.细针穿刺洗脱液中甲状腺球蛋白检测在诊断分化型甲状腺癌淋巴结转移中的应用进展[J].诊断学理论与实践，2020，19（4）：339-343.
[3]	Vaccarella S，Dal Maso L，Laversanne M，et al.The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence：A Population-Based Study in Selected High-Resource Countries[J].Thyroid，2015，25（10）：1127-1136.
[4]	Sung H，Ferlay J，Siegel RL，et al.Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin，2021，71（3）：209-249.
[5]	李云雪，王刚，孙备，等.甲状腺乳头状癌颈部淋巴结转移的处理态度和诊疗现状[J].实用肿瘤学杂志，2020，34（6）：530-534.
[6]	厉彦辰，郑鲁明，朱见，等.机器人手术与传统手术治疗甲状腺癌合并甲状腺功能亢进疗效对照研究[J].国际外科学杂志，2019，46（12）：834-839.
[7]	Antonelli A，La Motta C.Novel therapeutic clues in thyroid carcinomas：The role of targeting cancer stem cells[J].Med Res Rev，2017，37（6）：1299-1317.
[8]	Fallahi P，Ferrari SM，Galdiero MR，et al.Molecular targets of tyrosine kinase inhibitors in thyroid cancer [J].Semin Cancer Biol，2022，79：180-196.
[9]	Cabanillas ME，McFadden DG，Durante C.Thyroid cancer[J].Thyroid cancer[J].Lancet，2016，388（10061）：2783-2795.
[10]	Cooper DS，Doherty GM，Haugen BR，et al.Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid，2009，19（11）：1167-1214.
[11]	Van Nostrand D，Atkins F，Yeganeh F，et al.Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma[J].Thyroid，2002，12（2）：121-134.
[12]	刘斌，王建涛，牟达，等.131I 治疗分化型甲状腺癌血液和骨髓的吸收剂量及剂量学导向治疗法[J].中华核医学与分子影像杂志，2010，30（2）：142-144.
[13]	Lassmann M，Luster M，Hanscheid H，et al.Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer[J].J Nucl Med，2005，46（5）：899-901.
[14]	王秋，王治国，张国旭，等.碘131I 治疗69 例分化型甲状腺癌的临床观察[J].辽宁医学杂志，2015，29（1）：55-56.
[15]	罗全勇，陈立波，余永利，等.131I 治疗后分化型甲状腺癌患者外周血淋巴细胞亚群的变化[J].中华内分泌代谢杂志，2006，22（1）：52-54.
[16]	王建涛，赵卫威，刘斌，等.131I 治疗对青少年分化型甲状腺癌患者外周血的影响[J].生物医学工程学杂志，2011，28（6）：1185-1188.
[17]	李慧，郭宁，张英杰，等.分化型甲状腺癌131I 治疗前后外周血细胞的动态变化[J].中华核医学与分子影像杂志，2015，35（2）：116-119.
[18]	尚毓，蒋华.放射性131I 对老年甲状腺癌患者白细胞的影响[J].中国老年学杂志，2015，35（3）：661-662.
[19]	中华医学会核医学分会.131I 治疗分化型甲状腺癌指南（2021 版）[J].中华核医学与分子影像学杂志，2021，41（4）：24.
[20]	李小亮，陈尔东，刘建香，等.我国现行职业性放射性疾病诊断标准概况[J].中国职业医学，2021，48（2）：6.
[21]	Hyer S，Vini L，O′Connell M，et al.Testicular dose and fertility in men following I（131） therapy for thyroid cancer[J].Clin Endocrinol （Oxf），2002，56（6）：755-758.
[22]	Garsi JP，Schlumberger M，Rubino C，et al.Therapeutic administration of131I for differentiated thyroid cancer：radiation dose to ovaries and outcome of pregnancies[J].J Nucl Med，2008，49（5）：845-852.
[23]	Sioka C，Kouraklis G，Zafirakis A，et al.Menstrual cycle disorders after therapy with iodine-131[J].Fertil Steril，2006，86（3）：625-628.
[24]	Vini L，Hyer S，Al-Saadi A，et al.Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer[J].Postgrad Med J，2002，78（916）：92-93.
[25]	van Velsen EFS，Visser WE，van den Berg SAA，et al.Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer[J].Thyroid，2020，30（4）：580-587.
[26]	Nies M，Cantineau AEP，Arts EGJM，et al.Long-Term Effects of Radioiodine Treatment on Female Fertility in Survivors of Childhood Differentiated Thyroid Carcinoma[J].Thyroid，2020，30（8）：1169-1176.
[27]	刘斌，黄蕤，郭佳，等.131I 治疗分化型甲状腺癌对患者生殖健康的影响[J].中华核医学与分子影像杂志，2014，34（4）：323-326.
[28]	杨凡慧，王琴，彭一檬，等.分化型甲状腺癌多学科联合治疗临床疗效评价15年随访研究[J].泸州医学院学报，2015，8（4）：371-374.
[29]	周永增.辐射防护的生物学基础[J].辐射防护通讯，2006，26（4）：1-7.
[30]	Yu CY，Saeed O，Goldberg AS，et al.A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer[J].Thyroid，2018，28（12）：1662-1673.
[31]	Greenspan BS.Radioiodine Treatment of Well-Differentiated Thyroid Cancer：Balancing Risks and Benefits[J].J Clin Oncol，2018，36（18）：1785-1787.
[32]	陈可婧，赵惠扬，曾文生，等.甲状腺转移癌碘-131 治疗后并发肺癌1 例报告[J].中华放射医学与防护杂志，1994，14（2）：121-122.
[33]	Harness JK，Thompson NW，Sisson JC，et al.Proceedings：Differentiated thyroid carcinomas. Treatment of distant metastases[J].Arch Surg，1974，108（4）：410-419.
[34]	余永莉，罗全勇，陈立波，等.分化型甲状腺癌术后131I治疗生存率分析[J].中华核医学杂志，2006，26（5）：261-263.
[35]	Kukkar SR，Panchal H，Anand A.Primary neuroendocrine carcinoma of the thymus：A retrospective analysis from a regional cancer center in Western India[J].Indian J Cancer，2017，54（3）：556-559.
[36]	国家质量监督检验检疫总局.GB18871-2002，电离辐射防护与辐射源安全基本标准[S].
[37]	贾强，何雅静，孟召伟，等.甲状腺癌131I 清甲治疗病房环境辐射安全性探讨[J].中国医学创新，2011，8（16）：26-28.
[38]	Monsieurs M，Thierens H，Dierckx RA，et al.Real-life radiation burden to relatives of patients treated with iodine-131：a study in eight centres in Flanders （Belgium）[J].Eur J Nucl Med，1998，25（10）：1368-1376.